INDICATIONS AND USAGE
COVIRIN in combination with Direct-acting antivirals (DAA) including Sofosbuvir, Daclatasvir, Ledipasvir, Velpatasvir etc, or with Interferons is indicated for the treatment of patients with chronic hepatitis C (CHC) virus infection who have compensated liver disease.
The following points should be considered when initiating Ribavirin combination therapy with DAA or with Interferons:
- Safety and efficacy data are not available for treatment longer than 48 weeks.
- The safety and efficacy of Ribavirin and DAA therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy.
- The safety and efficacy of Ribavirin therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin should not be used for these indications.
